Group One Trading’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.9K | Sell |
500
-1,400
| -74% | -$28.8K | ﹤0.01% | 6256 |
|
|
2026
Q1 | $36.5K | Sell |
1,900
-3,300
| -63% | -$65.7K | ﹤0.01% | 5506 |
|
|
2025
Q4 | $85.9K | Buy |
5,200
+3,900
| +300% | +$65.8K | ﹤0.01% | 5128 |
|
|
2025
Q3 | $18.9K | Sell |
1,300
-9,500
| -88% | -$137K | ﹤0.01% | 6734 |
|
|
2025
Q2 | $151K | Buy |
10,800
+300
| +3% | +$4.22K | ﹤0.01% | 4608 |
|
|
2025
Q1 | $143K | Buy |
10,500
+9,500
| +950% | +$182K | ﹤0.01% | 4298 |
|
|
2024
Q4 | $20.4K | Hold |
1,000
| – | – | ﹤0.01% | 5672 |
|
|
2024
Q3 | $29.1K | Sell |
1,000
-2,000
| -67% | -$49.6K | ﹤0.01% | 5009 |
|
|
2024
Q2 | $69.7K | Buy |
+3,000
| New | +$57.6K | ﹤0.01% | 4260 |
|
|
2024
Q1 | – | Sell |
-100
| Closed | -$2.15K | – | 7224 |
|
|
2023
Q4 | $2.15K | Hold |
100
| – | – | ﹤0.01% | 6799 |
|
|
2023
Q3 | $2.06K | Sell |
100
-3,600
| -97% | -$91.3K | ﹤0.01% | 7030 |
|
|
2023
Q2 | $109K | Buy |
+3,700
| New | +$104K | ﹤0.01% | 4521 |
|
|
2023
Q1 | – | Sell |
-3,800
| Closed | -$106K | – | 7354 |
|
|
2022
Q4 | $106K | Buy |
3,800
+2,000
| +111% | +$59.5K | ﹤0.01% | 4395 |
|
|
2022
Q3 | $55K | Buy |
1,800
+1,400
| +350% | +$45.5K | ﹤0.01% | 5320 |
|
|
2022
Q2 | $12K | Buy |
400
+300
| +300% | +$7.86K | ﹤0.01% | 6645 |
|
|
2022
Q1 | $3K | Buy |
+100
| New | +$3.44K | ﹤0.01% | 7616 |
|
|
2021
Q4 | – | Sell |
-400
| Closed | -$20K | – | 8330 |
|
|
2021
Q3 | $20K | Sell |
400
-200
| -33% | -$11.3K | ﹤0.01% | 7172 |
|
|
2021
Q2 | $47K | Sell |
600
-18,000
| -97% | -$1.11M | ﹤0.01% | 6634 |
|
|
2021
Q1 | $1.06M | Buy |
18,600
+11,200
| +151% | +$750K | ﹤0.01% | 3156 |
|
|
2020
Q4 | $620K | Sell |
7,400
-500
| -6% | -$30.2K | ﹤0.01% | 3083 |
|
|
2020
Q3 | $283K | Buy |
7,900
+7,200
| +1,029% | +$217K | ﹤0.01% | 3363 |
|
|
2020
Q2 | $17K | Sell |
700
-16,000
| -96% | -$376K | ﹤0.01% | 4890 |
|
|
2020
Q1 | $292K | Buy |
16,700
+15,200
| +1,013% | +$317K | ﹤0.01% | 2447 |
|
|
2019
Q4 | $26K | Buy |
+1,500
| New | +$25K | ﹤0.01% | 4275 |
|
|
2019
Q3 | – | Sell |
-1,000
| Closed | -$21K | – | 5224 |
|
|
2019
Q2 | $21K | Sell |
1,000
-900
| -47% | -$20.2K | ﹤0.01% | 4149 |
|
|
2019
Q1 | $44K | Buy |
+1,900
| New | +$39.8K | ﹤0.01% | 3625 |
|
|
2018
Q4 | – | Sell |
-300
| Closed | -$7K | – | 4973 |
|
|
2018
Q3 | $7K | Hold |
300
| – | – | ﹤0.01% | 4742 |
|
|
2018
Q2 | $5K | Buy |
+300
| New | +$5.65K | ﹤0.01% | 4801 |
|
Other funds holding DNLI
Group One Trading's DNLI Position: Q2 2026 in Review
Group One Trading opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 776 shares worth $20K. The stake represents ﹤0.01% of the portfolio and ranks #6025 among its holdings. This is a return to the name: Group One Trading previously reported a position in DNLI as recently as Q3 2024.
Group One Trading first reported a position in DNLI in Q4 2018 and has held it in 11 quarters since. The position peaked at $1.15M in Q1 2023. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Group One Trading held 776 shares of Denali Therapeutics worth $20K as of Q2 2026.
- Denali Therapeutics was a new Group One Trading position in Q2 2026.
- Denali Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6025 holding.
- Group One Trading first reported a position in Denali Therapeutics in Q4 2018 and has held it in 11 quarters since.
- Group One Trading's Denali Therapeutics position peaked at $1.15M in Q1 2023.
- 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.